Crispr Therapeutics AG (NASDAQ:CRSP) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $74.00 and last traded at $72.61, with a volume of 447290 shares changing hands. The stock had previously closed at $73.13.
Several brokerages recently commented on CRSP. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a research report on Tuesday, November 26th. Roth Capital boosted their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research note on Tuesday, November 19th. William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. Finally, TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Crispr Therapeutics presently has an average rating of “Buy” and an average price target of $69.54.
The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $3.96 billion, a PE ratio of -20.97 and a beta of 3.30. The business’s 50-day simple moving average is $52.76 and its 200-day simple moving average is $46.89.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by corporate insiders.
A number of large investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC raised its position in shares of Crispr Therapeutics by 5.9% in the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock worth $839,000 after acquiring an additional 986 shares during the period. Moody Aldrich Partners LLC acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth about $1,838,000. Traynor Capital Management Inc. purchased a new position in Crispr Therapeutics in the 2nd quarter valued at about $308,000. Nikko Asset Management Americas Inc. lifted its stake in Crispr Therapeutics by 324.3% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after buying an additional 1,430,364 shares in the last quarter. Finally, BNP Paribas Arbitrage SA acquired a new stake in Crispr Therapeutics in the 2nd quarter worth about $41,000. 49.81% of the stock is owned by institutional investors.
Crispr Therapeutics Company Profile (NASDAQ:CRSP)
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.